- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01676298
Spartan FRX Project Reproducibility Study
Study of the Analytical Reproducibility of the Spartan FRX CYP2C19 *2,*3 and *17 Genotyping System.
Study Overview
Status
Intervention / Treatment
Detailed Description
The FRX system is comprised of hardware and consumable components. The hardware components of the system include an Analyzer (thermal cycler with fluorescence detection capability), a notebook computer and a printer. The consumable component of the FRX system is a sample collection kit. Each kit contains a buccal swab (used to collect the patient sample) and a tube containing the reagents required for genomic DNA extraction and PCR (polymerase chain reaction) amplification stages of the test.
The Spartan FRX System is capable of detecting three CYP2C19 SNPs(single nucleotide polymorphism) (*2, *3, *17) in each test performed. An individual sample collection kit is required for each SNP tested; therefore three sample collection kits are required for each test performed on the system.
To perform a test, the user collects three buccal samples from the patient and then inserts a sample into each of the three reagent tubes (one for each of the CYP2C19 loci *2, *3 and *17). The reagent tubes are placed into the Analyzer and the FRX system automates the processes of DNA extraction, PCR amplification, fluorescent signal detection and data analysis. The system provides the user with a printed result listing the patient genotypes at the *2, *3 and *17 loci.
The objective of the study is to evaluate the performance of the FRX System under multivariate conditions. Specifically, the following variables will be included in the study:
- Test site - x3
- Operator - x6 (2 per site)
- Day - x15 (5 non-consecutive days per site)
- FRX System - x16
Test performance is defined as the number of correct genotype calls, expressed as a percentage of the total number of tests performed on the system.
For both the first-pass and second-pass results, 1-sided 95% confidence lower limits will be calculated using the score method for the % correct calls (i.e. % agreement).
Genotype results from the FRX system will be compared with results of DNA sequencing. The result of the FRX System test will be determined to be correct if the genotype calls for all three SNPs are identical to the genotypes determined by DNA sequencing for that sample/individual.
Results of the Reproducibility Study will be acceptable if the lower bound of a 1-sided 95% confidence limit of the total correct call rate per genotype is greater than or equal to 95%, based on second-pass results.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Hospital Research Institute
-
Ottawa, Ontario, Canada, K1H 8L6
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Canada, M5G 1Z5
- Mount Sinai Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Above 16 years of age
- Must have required genotype
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Correct Calls to Assess Reproducibility of the Spartan FRX CYP2C19 System.
Time Frame: After second pass result is complete (~3h)
|
Reproducibility was calculated as a percentage of the correct calls over the total calls made for each genotype group. All calls were made using the Spartan FRX CYP2C19 genotyping diagnostic system. All data analyses was qualitative, based on the genotype calls determined by the FRX system (using on-board automated data analysis). A printed result listing the genotype call for each SNP was generated by the FRX system at the end of each run. If the result of a test is "Inconclusive" for one or more SNPs, the test were immediately repeated for the corresponding SNP(s) only, per the instructions for use. Results are reported based on both first-pass and second-pass (i.e. repeated test). For both the first-pass and second-pass results, 1-sided 95% confidence lower limits were calculated using the score method for the % correct calls (i.e. % agreement). |
After second pass result is complete (~3h)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Chris JE Harder, PhD, Spartan Bioscience
- Principal Investigator: Azar Azad, PhD, Mount Sinai Hospital
- Principal Investigator: Marc Desjardins, PhD, Ottawa Hosptial Research Institute
- Principal Investigator: Jean McGowan-Jordan, PhD, Children's Hospital of Eastern Ontario
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 01001686
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Analytical Reproducibility of a Medical Device
-
Tomey CorporationCompletedEvaluate the Agreement and Precision of Device SS-1000 and the Predicate Device the Pentacam in a Reproducibility and Repeatability TrialJapan
-
Universitair Ziekenhuis BrusselCompletedHealth Care Utilization | Availability of the Different Types of Anesthesia Neuromuscular Monitoring Devices Throughout European Hospitals | Medical Device Availability | Medical Staff AvailabilityBelgium
-
University College Hospital GalwayCompletedPerformance and Safety of a New Supraglottic Airway DeviceIreland
-
University of Colorado, DenverRecruitingInflammation Caused by the Placement of a Temporary Anchorage DeviceUnited States
-
GE HealthcareCompletedGather Feasibility Data and User Feedback on Use of a Device in Vivo on Pregnant Volunteers in Their 2nd and 3rd TrimesterUnited States
-
University of NebraskaCompletedAir Embolism as A Complication of Medical CareUnited States
-
Rigshospitalet, DenmarkCopenhagen Academy for Medical Education and SimulationCompletedMedical Education | Bladder Cancer | Validity-evidence for a Simulator-based Test | Virtual Simulation | Surgical Skill Training | Transurethral Resection of BladdertumorsDenmark
-
University Hospital, Clermont-FerrandDiagnostica StagoRecruitingPatients Without a Medical History of Thrombosis or Hemorrhage | Hemophilic Patient | Patient With FV Leiden Mutation | Patient With Cirrhosis | Patient on AnticoagulantFrance
Clinical Trials on Spartan FRX CYP2C19 Test System
-
Spartan Bioscience Inc.Mount Sinai Hospital, CanadaCompletedGenotyping TechniquesCanada
-
Spartan Bioscience Inc.Mount Sinai ServicesCompleted
-
Spartan Bioscience Inc.The Ottawa Hospital; Children's Hospital of Eastern Ontario; The University of...Completed
-
Spartan Bioscience Inc.BeaufortCompleted
-
Ottawa Heart Institute Research CorporationActive, not recruiting
-
Spartan Bioscience Inc.Completed
-
Spartan Bioscience Inc.The Ottawa Hospital; Humber River HospitalCompleted
-
Advocate Health CareCompletedDelirium, Cytochrome P-450 Enzyme SystemUnited States
-
University of Puerto RicoNational Institute on Minority Health and Health Disparities (NIMHD); Icahn...Active, not recruitingMyocardial Infarction | Coronary Artery Disease | Stroke | Peripheral Arterial Disease | Acute Coronary Syndrome | Cardiovascular Disease (CVD)Puerto Rico
-
Medical University of WarsawUniversity of Pecs; Polish Cardiac SocietyUnknownStable AnginaPoland, Hungary